Dechra Pharmaceutical shares a ‘long-term value hold'

Dechra Pharmaceuticals CEO Ian Page says they will continue to see continued growth in the US, a steady increase in presence in the rest of the world, and their product portfolio will continue to deliver results.

He says they are looking to maintain double-digit underlying earnings growth in FY16. In regards to the share price, he feels it got overheated but has found its natural level, and if they keep delivering growth the share price will look after itself.

Trade now

Live Dechra Pharmaceuticals prices

The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication.